KioMedine - Model vs One -Unique Soft Implant for OsteoArthritis Treatment
Unique soft implant for sustainable OsteoArthritis pain relief and outstanding response rate. KioMedinevsone is the new generation single-shot injection intended for the symptomatic treatment of knee OsteoArthritis based on world-first exclusive animal-free KiOmedine® CM-Chitosan. Thanks to a unique structure that differs from hyaluronic acid, KioMedinevsone has an exclusive dual mechanism of action to tackle OA pain and other symptoms.
KiOmedine® CM-Chitosan enhances lubrication of the damaged cartilage and protects the synovial fluid through the scavenging of free radicals.
This dual mechanism of action contributes to significantly reduce OA pain, better reduces joint frictions and provides better knee mobility with a long-lasting relief.
The KiOmedine® CM-Chitosan technology enables the development of a resorbable implant with unique degradation resistance and up to 1-month residence time in the joint2.
KiOmed Pharma`s innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative.
The patented technology KiOmedine® CM-Chitosan offers competitive advantages thanks to its immune-compatibility and unique structure. Our scientific team has conducted a large number of safety and efficacy studies to demonstrate the unrivaled properties of our KiOmedine® CM-Chitosan technology in various applications :
- Excellent lubrication properties
- Outstanding scavenging capacity
- High ability to protect tissues against oxydative stress
KiOmedine® CM-Chitosan brings high clinical value to therapeutic solutions and is a technology of choice, suitable for injectable formulations and implantable devices.
- KiOmedine® brings unique clinical value in
- high impact pathologies and major social burdens
- Invalidating OsteoArthritis
KioMedinevsone is the first fluid implant intended to treating OsteoArthritis, an invalidating pathology that affects more than 100 millions of patients worldwide.
The unique character of KiOmedine® resides in its innovative chemical design and non-animal origin that allow developing safe medical devices to offer high clinical efficacy thanks to tunable attributes such as lubrication and combating free-radical species.
Skin Aging
Thanks to free radical scavenging, KiOmedine®-based dermal fillers provide tunable tissues filling properties with unique skin protection and hydration while stimulating collagen synthesis.
Dry Eye Disease
Thanks to its unique hydrating and lubricating properties, as well as its ability to protect tissues against oxidative stress, KiOmedine® is a component of choice in eyedrops formulations or for more innovative treatments of the posterior segment.
In a randomized single-blind APROOVE clinical trial, the safety and efficacy of a single-injection of KioMedinevsone have been proven after injection in 64 patients2.
KioMedinevsone significantly reduces knee pain up to 6 months with a response rate up to 76% according to the OMERACT-OARSI response criteria thanks to a unique dual mechanism of actions combining improved lubrication and joint protection1.